The WHO's ECDD meeting will assess the critical reviews of a handful of substances, including the coca leaf, guiding future international scheduling decisions, with major implications for Indigenous rights.
As panic and geopolitics drive drug and bordering policy, harm reduction advocates find new ground at the UN — mobilising evidence, resisting disinformation, and taking the fight for rights to a global stage.
The INCB’s 2024 report highlights the global failure to ensure equitable access to controlled medicines for pain relief, palliative care, and harm reduction — urging urgent, rights-affirming reforms.
Trump has nominated Carter, a former right-wing journalist, to lead a tough-on-crime agenda at the Office of National Drug Control Policy, despite a lack of relevant experience.
Join C-EHRN’s webinar on 9 May to explore Europe’s emerging nitazene threat, addressing trends, health risks, policy responses, and harm reduction strategies.
D4DPR argues that money from opioid litigation settlements should also be used for overdose prevention centres to mitigate future death and mortality and improve the quality of life for those who use drugs.
A new course hosted online and in person at the University of Geneva will explore current events and evolving perspectives around international drug policy and controlled substances.
In light of the grave threats posed by nitazenes in Australia, experts call for political support and scaling-up of drug checking services to reduce fatalities.